|
Relationship of covariates to blood glucose and HbA1c measurements |
||||||
| Glucose (mg/dl) |
HbA1c (%) |
|||||
|
|
|
|||||
| Variables |
LS mean ± SE |
(95% CI) |
P value |
LS mean ± SE |
(95% CI) |
P value |
|
|
||||||
| Sex |
0.2268 |
0.8062 |
||||
| Female |
107.80 ± 1.34 |
(105.15, 110.44) |
5.51 ± 0.10 |
(5.31, 5.71) |
||
| Male |
109.70 ± 1.07 |
(107.58, 111.81) |
5.48 ± 0.07 |
(5.33, 5.64) |
||
| Age, years |
0.075 |
0.3041 |
||||
| 20–49 |
105.09 ± 2.10 |
(100.96, 109.22) |
5.33 ± 0.15 |
(5.01, 5.64) |
||
| 50–59 |
108.83 ± 1.75 |
(105.38, 112.27) |
5.44 ± 0.13 |
(5.17, 5.71) |
||
| 60–69 |
109.69 ± 1.43 |
(106.88, 112.51) |
5.62 ± 0.10 |
(5.42, 5.83) |
||
| 70< |
111.37 ± 1.32 |
(108.77, 113.97) |
5.61 ± 0.09 |
(5.42, 5.79) |
||
| Medication |
0.4579 |
0.6887 |
||||
| candesartan cilexetil |
110.93 ± 1.31 |
(108.34, 113.51) |
5.62 ± 0.10 |
(5.41, 5.82) |
||
| losartan potassium |
107.73 ± 2.01 |
(103.77, 111.69) |
5.52 ± 0.12 |
(5.28, 5.77) |
||
| olmesartan medoxomil |
106.99 ± 2.24 |
(102.58, 111.40) |
5.37 ± 0.15 |
(5.06, 5.68) |
||
| telmisartan |
108.57 ± 2.16 |
(104.31, 112.83) |
5.43 ± 0.16 |
(5.10, 5.76) |
||
| valsartan |
109.51 ± 1.56 |
(106.44, 112.59) |
5.55 ± 0.12 |
(5.30, 5.81) |
||
| Treatment duration |
<.0001 |
0.6014 |
||||
| 0 = "Baseline" |
111.98 ± 1.16 |
(109.70, 114.27) |
reference* |
5.51 ± 0.07 |
(5.37, 5.66) |
reference* |
| 1 = "~3 M" |
105.86 ± 1.13 |
(103.64, 108.09) |
<.0001* |
5.50 ± 0.07 |
(5.35, 5.65) |
0.8209* |
| 2 = "3~6 M" |
107.78 ± 1.48 |
(104.87, 110.69) |
0.0081* |
5.44 ± 0.08 |
(5.28, 5.61) |
0.2582* |
| 3 = "6~12 M" |
109.36 ± 1.63 |
(106.16, 112.56) |
0.1308* |
5.54 ± 0.08 |
(5.37, 5.70) |
0.7457* |
|
Abbreviations: HbA1c, hemoglobin A1c; LS means, least squares means; SE, standard error; CI, confidence interval. *Dunnett-Hsu post-hoc analysis. | ||||||
Kitamura et al. Cardiovascular Diabetology 2007 6:26 doi:10.1186/1475-2840-6-26 |
||||||